

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
**WO 01/01129 A2**

(51) International Patent Classification<sup>7</sup>: G01N 33/48

(74) Agent: NILSSON, Brita; AB Stockholms Patentbyrå, Zacco & Bruhn, P.O. Box 23101, S-104 35 Stockholm (SE).

(21) International Application Number: PCT/EP00/05563

(22) International Filing Date: 16 June 2000 (16.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9902410-1 24 June 1999 (24.06.1999) SE

(71) Applicant (for all designated States except US): CAVIDI TECH AB [SE/SE]; Uppsala Science Park, S-751 83 Uppsala (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**


— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): KÄLLANDER, Clas [SE/SE]; Husbygård, Husbyborg, S-755 92 Uppsala (SE). GRONOWITZ, Simon [SE/SE]; Norbyvägen 51, S-752 39 Uppsala (SE). PETTERSSON, Ingvar [SE/SE]; Stagneliusgatan 2, S-754 22 Uppsala (SE).

(54) Title: REVERSE TRANSCRIPTASE ASSAY KIT, USE THEREOF AND METHOD FOR ANALYSIS OF RT ACTIVITY IN BIOLOGICAL SAMPLES



(57) Abstract: A reverse transcriptase (RT) assay kit for analysis of RT activity in biological samples is described. The kit comprises solid phase bound prA and/or pdA template(s) obtainable by contacting a polystyrene-based solid phase with a 1-methylimidazole-containing coupling solution, and RT-type adapted assay components selected from a buffer, divalent metal ion, chelator, polyamine, RNase inhibitor, reducing agent, salt, stabilizing agent, and detergent, and deoxynucleotide triphosphate, primer, protective agent and concentrated washing buffer, and optionally lyophilized reference enzyme(s), and further optionally lyophilized alkaline phosphatase conjugated anti-BrdU monoclonal antibody, alkaline phosphatase substrate buffer and alkaline phosphatase substrate, and written instructions for use of the assay kit. Further, a method and a use of the assay kit for the qualitative and quantitative analysis of RT activity in a biological sample, optionally followed by evaluation of the status of a RT activity related disorder or disease based on the result of the analysis of the RT activity, are disclosed.

WO 01/01129 A2

**Reverse transcriptase assay kit, use thereof and method for analysis of RT activity in biological samples.**

The present invention relates to a reverse transcriptase (RT) assay kit for analysis of RT activity in biological samples. The invention also relates to a method and a use of the RT assay kit for the qualitative and quantitative analysis of RT activity in a biological sample, optionally followed by evaluation of the status of a RT activity related disorder or disease based on the result of the analysis of the RT activity.

**Background of the invention**

Reverse transcriptase (RT) is the crucial enzyme responsible for the synthesis of DNA from viral RNA for all retroviruses, including human immunodeficiency virus (HIV) (Baltimore-70, Temin -70, Barre-Sinoussi et al -83). This process involves three different enzymatic activities: synthesis of the first DNA strand, degradation of the viral RNA strand in the DNA/RNA hybrid, and synthesis of the second DNA strand (for a review see Goff).

Retroviruses can exist either in exogenous or endogenous forms or both. The main difference is that an endogenous retrovirus has entered the germline and thus its DNA is present in all cells of the organism, in contrast to an exogenous retrovirus which is only able to enter cells with the appropriate receptor for that specific virus. Endogenous retroviruses (ERVs) in humans are called HERVs. The integrated proviral form of an endogenous retrovirus has the same fundamental structure as that of an exogenous retrovirus. The integration of some HERVs into the germline is thought to have occurred 35 to 45 million years ago. These retroviral sequences constitute 1 % of the mammalian genome and hence also of the human genome. Thus, they are present in all human cells and inherited according to ordinary Mendelian laws.

Many families of HERVs are present in the human genome. The copy number per haploid human genome of HERVs varies between a single copy to thousands of copies for different families. The highest nucleotide sequence conservation is found in the pol gene. This feature has been used to derive relationship between HERV families. Although many of the HERVs and their ORFs are defective, mRNA transcripts have been detected from most HERV families in several tissue-types (reviewed in Wilkinson et al 1994, Leib-Mösch and Seifarth 1996). In addition, virion particles with polymerase and protease activity have been observed in normal human placentas, oocytes, teratocarcinomas, mammary carcinoma tissues and in salivary glands of some autoimmune patients (reviewed in Wilkinson et al. 1994, Urmovitz and Murphy 1996, Tönjes *et al.*, 1997 ). Stress conditions like anoxia and UV

irradiation might also induce the expression of HERVs as been observed for infectious retroviruses (reviewed by Duvic 1995).

Several HERVs have been localized to chromosomal breakpoints within the genome (Di Cristofano et al. 1995, Meese et al. 1996). Recombination between HERV  
5 sequences located at different chromosomal sites may cause genomic rearrangements including translocations, inversions, duplications and deletions. Such recombinatorial events are responsible for generating genomic instability that is an important feature of evolution. In addition, many tumors are characterised by specific genomic rearrangements thought to play a crucial role in the tumorigenesis. The relationship between presence of infectious retroviruses  
10 and development of tumors in the host suggests that HERVs are associated with cancer. Virion particles and retrovirus related antigens are frequently observed in primary tumor samples also in the absence of infectious viruses (Weiss 1984, Faff et al. 1992). In addition, antibodies directed to retroviral proteins have been demonstrated in the sera of patients with cancer (Weiss 1984). Moreover, HERV sequences are found to be highly expressed in certain  
15 tumor derived cell lines (reviewed in Löwer et al. 1996).

Endogenous proviruses can also recombine with exogenous variants (Martinelli et al. 1990). Novel recombinants receive an altered phenotype. This might contribute to the rapid evolution of new infectious retroviruses. The env gene is mainly affected since mutations in other parts may be deleterious and not compatible with particle formation. Some retroviral  
20 strains are found to be symbiotic in one species and pathogenic in another. These findings indicate a severe problem in xenotransplantations. Symbiotic ERVs provided by the transplanted tissues could be pathogenic in the new host. They might be able to interact with cell surface receptors needed for retroviral fusion present on cells of the new host. In addition, recombination with endogenous retroviral sequences within the genome of the tissue recipient  
25 can occur and create new infectious retroviruses that might spread in the population. Both endogenous and exogenous retroviruses can contribute to vertical and horizontal transmission of genetic material within and between species and provide mechanisms for evolution of new pathogenic agents.

Both infectious retroviruses and ERVs have been found to exhibit immuno-  
30 regulatory functions (reviewed in Krieg et al. 1992). These effects have mainly been studied in mice but there are some observations that support existence of similar mechanisms for HERVs. If HERV sequences can deregulate an immune response they can cause autoimmune diseases. These effects could be directly modulated by HERV proteins or indirectly by influencing the expression of molecules involved in the immune response. HERV proteins can

be exposed on the cell surface. Loss of self tolerance towards these protein sequences could cause autoimmune reactions against cells exposing them. Antibodies produced following retroviral infection might be crossreactive with HERV encoded proteins and responsible for loss of tolerance. This phenomenon has been observed in transgenic mice (Zinkernagel et al. 1990). In addition, loss of tolerance to ERV encoded env proteins was observed in mice that spontaneously developed an autoimmune glomerulonephritis (reviewed in Krieg et al. 1990 and 1992). Some observations in humans might support existence of crossreactive antibodies between endogenous and exogenous retroviral proteins. Antibodies against retroviral proteins have been detected in sera of autoimmune patients (reviewed in Krieg et al. 1992, Umovitz and Murphy 1996). In certain cases, the sera were found to react also with exogenous retroviruses. Retroviral infections have been associated with the onset of autoimmune diseases (reviewed in Krieg et al. 1990 and 1992). Moreover, infectious retroviral proteins show partial similarity to self antigens that are frequent targets for autoantibodies (reviewed in Krieg et al 1992). They could trigger autoimmune responses towards such targets, a mechanism referred to as molecular mimicry. However, similarities of HERV proteins to known self antigens have not yet been detected.

Assays for RT activity have become accepted techniques for the detection and quantification of retroviruses in cell cultures. They are together with p24 antigen assays used as confirmatory tests for HIV isolation (Jackson -88, Gupta-87). RT is also one of the main targets in the attempt to find efficient antivirals against HIV. A conventional RT activity assay is performed by utilizing a soluble enzyme assay with an artificial template-primer construction and tritiated deoxynucleotide triphosphate as nucleotide substrate (Baltimore-71, Lee et al -87). This early system was based on detection of incorporation of radioactivity into trichloroacetic-acid (TCA) precipitable RNA/DNA hybrids. Use of beta emitting nucleotides requires the use of scintillation fluids for detection of radioactivity, which often results in poor reproducibility due to quenching problems. This method is relatively cumbersome and not easily adapted to large scale screening of large numbers of samples. It is also very sensitive to the effects of disturbing factors in the samples.

During the last decade of intensive research on HIV, the RT assay has been improved using different techniques. The introduction of  $I^{125}$  labeled substrate gave an increased sensitivity and eliminated quenching and the use of scintillation fluids (Neumüller et al -90). The introduction of templates or primers linked to solid phases simplified the separation between substrate and product, eliminated the need of TCA precipitations and resulted in a "one tube RT assay" (Gronowitz et al -90, EP 0 447 442 B1).

More recently the use of radioactivity as label in RT assay has been eliminated by the use of modified nucleotide bases containing either antigenic eptiopes or structures with high affinity to defined ligands. The presence of these epitopes or structures in the newly synthesized RNA/DNA hybrid is then used for binding of antibodies or ligands conjugated with  
5 e.g. ELISA enzymes. The amount of ELISA enzymes bound is then determined in a secondary enzyme assay.

Porstmann et al 1991 utilizes 5- bromo-deoxyuridine (BrdU) triphosphate as nucleotide substrate in RT assay. The amount of BrdUMP incorporated is in a secondary step determined in an immunoassay using alkaline phosphatase conjugated monoclonal anti-BrdU  
10 antibodies.

Eberle and R. Seibl 1992 measure the incorporation of digoxigenin labeled dUTP into newly synthesized DNA instead of radioactively labeled dTTP. To be able to perform the separation of non-incorporated nucleotides from the newly synthesized DNA, biotin labeled dUTP is also added to the reaction mixture. After reverse transcription, the newly synthesized  
15 double labeled DNA is immobilized on streptavidin coated ELISA wells and evaluated photometrically by binding of peroxidase-conjugated anti-digoxigenin-antibodies. This procedure has been the base for a kit RT-assay which is commercially available from Boehringer Mannheim.

Urabe et al 1994 has developed a non-radioactive RT-assay based on  
20 incorporation of biotin-dUTP in an immobilized odT/prA construct. The amount of incorporated nucleotide substrate is measured photometrically after addition of streptavidin conjugated alkaline phosphatase. Closest prior art to the current invention was developed by Ekstrand et al 1996. In that assay poly (rA) covalently bound to the wells of a 96 well microtiter plate serves as template for the incorporation of BrdUMP during the reverse transcription step. The  
25 amount of BrdUMP incorporated into DNA is then determined immunologically according to a similar procedure as used by Porstmann et al 1991. The method is available as RT determination kits from Cavid Tech, Uppsala, Sweden.

Another principle for detection of RT-activity, commercially exploited by NEN (New England Nuclear, USA), is utilization of sequence specific probes for detection of newly  
30 synthesized cDNA. The enzymatic reaction utilizes a heteropolymeric RNA molecule with a 20-base oligonucleotide primer complementary to the RNA sequences near the 5'-end. A complete cDNA strand is produced during the RT-reaction. After hydrolysis of the template RNA the cDNA is hybridized with two different oligonucleotide probes, the capture and the detection probe. The capture probe is used for binding the cDNA to a microplate well. The detection probe

is conjugated to horseradish peroxidase, which after washing to remove unused nucleotide substrate and free probes gives a color reaction.

The detection sensitivity in the last type of assay can be increased by polymerase chain reaction amplification of the cDNA produced by the RT reaction. The amplified DNA can thereafter be detected with different types of labeled probes (Silver 93, Heneine 1995, US5817457, US5849494).

For some applications of the knowledge of RT activity in biological samples it is desirable to use a RT assay giving quantitative results. Such applications comprise disease or disorder monitoring where RT assay results from measurements made at different times are to be compared, and diagnosing of diseases or disorders where the level of RT activity compared to standard levels indicates if the patient is at risk or in deed is suffering from the disease or disorder in question.

In some instances it is desirable to use an assay which is as sensitive as possible, i.e. is able to measure as small amounts of RT activity as possible, in biological samples, so that the presence and magnitude of RT activity can be related to disorders and diseases at an early stage.

#### **Description of the invention**

The present invention provides an RT assay which is easy to use for screening purposes and which is very sensitive for RT activity.

More precisely, the present invention is directed to a reverse transcriptase (RT) assay kit which comprises one or several package(s) containing solid phase bound polyriboadenylic acid (prA) and/or polydeoxyadenylic acid (pdA) template(s) obtainable by contacting a polystyrene-based solid phase with a coupling solution comprising 1-methylimidazole, and prA and/or pdA, followed by incubation, washing with a wash buffer, drying and packaging. The kit comprises also RT-type adapted separately packaged assay components selected from the group consisting of a mixture of or separately a buffer, pH $\approx$  7-8, divalent metal ion, chelator, polyamine, RNase inhibitor, reducing agent, salt, stabilizing agent, and detergent, and a mixture of or separately lyophilized deoxynucleotide triphosphate, primer, protective agent and concentrated washing buffer, and written instructions for use of the assay kit. Optionally the kit comprises lyophilized reference enzyme(s). Optionally, the kit further comprises components of a detection system comprising lyophilized alkaline phosphatase conjugated anti-BrdU monoclonal antibody, alkaline phosphatase substrate buffer and alkaline phosphatase substrate, such as pNPP tablets.

In a preferred embodiment of the RT assay kit according to the invention, the solid phase is a microtiter plate, and an aliquot of the coupling solution, which comprises 100 mM 1-methylimidazole, pH  $\cong$  5 - 7, and 0.5 - 2 mg/ml prA and/or pdA, is added to each well, followed by the incubation at a temperature of 10 - 60 °C for 0.5 - 10 h, and washing each well for the removal of the 1-methylimidazole with the wash buffer, which comprises Bis-Tris propane, pH  $\cong$  5 - 7.

In a particularly preferred embodiment of the RT assay kit according to the invention, 100  $\mu$ l of the coupling solution, which comprises 100 mM 1-methylimidazole, pH  $\cong$  6.25, and 1mg/ml prA and/or pdA, is added to each well, followed by the incubation at room temperature for  $\cong$  2 h, washing of each well with 2x300  $\mu$ l of the wash buffer, which comprises 10mM Bis-Tris propane, pH  $\cong$  6.25, drying the plates at 37 °C for  $\cong$  25 minutes and putting the plates in foil bags and vacuum sealing the bags.

In a further embodiment of the RT assay kit according to the invention, the assay components are selected from the group consisting of the buffers Tris and Hepes, pH  $\cong$  7-8, the divalent metal ions  $Mg^{2+}$  and  $Mn^{2+}$ , the chelators ethylenediaminetetraacetic acid (EDTA) and ethylene glycol-bis( $\beta$ -aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) and, the polyamines spermine and spermidine, the RNase inhibitors heparin sulfate and dextran sulfate, the reducing agents dithiothreitol (DTT), dithioerythritol (DTE), and glutathione, the salts NaCl and KCl, the stabilizing agents newborn calf serum (NCS) and bovine serum albumin BSA, the detergents Tween 20 and Triton X-100, the deoxynucleotide triphosphate BrdUTP, the primer oligo dT or oligo dN where N is another T analog such as U, and the protective agents ATP, GTP and CTP.

The present invention is also directed to the use of an assay kit according to the invention for the qualitative and quantitative analysis of RT activity in a biological sample, e.g. a biological sample which is selected from cell extracts and biological fluids, such as plasma, serum, spinal fluid, synovial fluid and pleural fluid.

In a preferred embodiment the use according to the invention is followed by evaluation of the status of a RT activity related disorder or disease based on the result of the analysis of the RT activity.

Additionally, the present invention is directed to a method of qualitative and quantitative analysis of RT activity in a biological sample comprising the steps of using and following the written instructions for the RT assay kit according to the invention for the determination of the RT activity in the biological sample, e.g. a biological sample which is

selected from cell extracts and biological fluids, such as plasma, serum, spinal fluid, synovial fluid and pleural fluid.

In a preferred embodiment the method according to the invention is followed by evaluation of the status of a RT activity related disorder or disease based on the result of the analysis of the RT activity.

The present invention will now be illustrated by reference to the drawings and a more detailed description of embodiments, but these embodiments should not be considered as limiting to the scope of protection defined in the appended claims.

#### **Short description of the drawings**

**Figure 1.** The RT activity was determined in a medium from a culture of the PK cell line with two methods. The absorbance values obtained were plotted against the amount media added to the reaction mixture.

**Figure 2.** Direct RT determination in synovial fluid samples collected from patients suffering from rheumatoid arthritis. The values plotted were obtained from 1  $\mu$ l samples and an over-night RT reaction.

**Figure 3.** The RT activity was determined in an extract from a breast cancer with two methods. The absorbance values obtained are plotted against the amount of extract added to the reaction mixture.

**Figure 4.** Direct determination of RT activity in extracts from breast cancer biopsies. The absorbance values plotted against the protein concentration in each sample were obtained from 1  $\mu$ l extract and an over-night RT reaction.

**Figure 5.** The RT activity in a A) medium of a culture of HTLV 1 transformed cells and a B) medium from a BLV infected culture were determined with two methods. The absorbance values obtained were plotted against the amount of sample added to the reaction mixture.

**Figure 6.** Direct determination of RT activity in serum from SIV infected macaques. The absorbance values obtained in a 4-hour RT assay were plotted against serum sampling day.

#### **DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION**

The RT assay kit of the invention comprises three different types of components, namely

- 1) A template consisting of polyriboadenylic acid (prA) or polydeoxyadenylic acid (pdA) attached to a solid phase.



- 2) Reaction mixtures that allow the enzymes to polymerise a new DNA strand in a primer-dependent manner using the attached template polynucleotide.
- 3) Components of a detection system for the immunological detection of the in vitro synthesized DNA strand.

1) *Solid phase bound template*

A method has been developed whereby prA or pdA can be attached to certain types of microtiter plates in a manner that allows the polynucleotides to serve as templates for primer-dependent dNTP incorporation by viral and cellular RNA- and DNA- dependent DNA polymerases (reverse transcriptases, RTs). It has been shown to work on two commercially available microtiterplates, CovaLink™ and NucleoLink™ from Nalge Nunc International. The prA coupled microtiter plates used for the assay kits according to the invention are produced from NucleoLink™ strips. The procedure and the buffers are described in Table 1. The mechanism of the binding is not known as the procedure does not correspond to methods recommended or suggested by the manufacturer or is explicitly stated in the literature. A possible reaction mechanism involves reactive groups introduced during the manufacturing procedure but other than those grafted on for the known and intended use of that specific surface. Similar results are expected to be obtained with other polystyrene-based microtiter plates from other commercial sources. A method for chemically activating polystyrene to get a surface with properties equal to those of the CovaLink™ plates has been published (Zammatteo et al -96). Several other methods for attaching polynucleotides to plastic surfaces have also been published (Zammatteo et al -96, Gregorius et al -95, Niveleau et al -93, Rasmussen et al -91, Ghosh and Musso -87).

2) *RT type adapted reaction mixtures*

The general conditions for obtaining nucleotide incorporation by RNA- and DNA- dependent DNA polymerases in soluble systems using purified enzymes are simple and well known. They include a buffer keeping the pH around 7.5, a divalent metal ion,  $Mg^{2+}$  or occasionally  $Mn^{2+}$ , a salt to adjust the ionic strength, for some enzymes a reducing agent and a bit of detergent. Provided with this simple reaction buffer the enzymes will be able to utilize added template, primer and deoxynucleotide triphosphates to synthesize a DNA strand.

This general concept takes no account of the differences in optimal or especially adapted reaction conditions that are required between different classes or types of reverse transcriptases. Another important aspect is the desired ability of the reaction mixture to

tolerate addition of untreated biological fluids or cell extracts as the source of the RT enzymatic activity.

Systematic testing using both crude samples such as cell culture supernatants and purified enzymes revealed other reaction components that were used to create reaction mixtures optimized or especially adapted for specific reverse transcriptases.

Table 2 contains a summary of the components used to compose the individual RT type adapted reaction mixtures. The compositions of typical reaction mixtures are presented in Table 3.

The reverse transcriptase assay method of the invention is performed as described below. The first step in the assay is to add 100  $\mu$ l of reaction mixture to each well of the prA-coupled microtiter plate, followed by a 20-60 min pre-incubation at 33°C. The sample containing the reverse transcriptase is then added in 50  $\mu$ l of buffer, giving a final assay volume of 150  $\mu$ l, and the microtiter plate is then incubated at 33°C. Each sample is added to duplicate microtiter plates to allow for two assay times, standardized to 3 hours and overnight, meaning 16-20 hours. A step-by-step procedure is provided in the written instructions or user's manual included with each kit. It contains suggestions or instructions on how to adapt the generic reverse transcriptase assay components for some or all of the following applications: 1) Quantification of RT activity. 2) Screening of RT activity in cell extracts, cell supernatants and/or biological fluids including but not limited to plasma, serum, spinal fluid, synovial fluid and pleural fluid. 3) Determination of RT activity blocking antibody. 4) Determination of IC<sub>50</sub> values of RT activity inhibiting substances.

Using these reaction mixtures and the solid phase bound templates we designed the claimed assays which were either more sensitive in direct measurements of RT activity than other previously described assays based on solid phase bound templates or allowed detection of previously unknown reverse transcriptase activities.

### 3. Immunological detection of the *in vitro* synthesized DNA strand.

The polymerase in the sample synthesizes a DNA strand using the Bromo-deoxyuridine triphosphate (BrdUTP) provided in the reaction mixture.

The incorporated BrdUMP is detected by a BrdU binding monoclonal antibody conjugated to alkaline phosphatase. The alkaline phosphatase activity of the bound antibody is then quantified by adding a substrate solution- containing para-nitro phenyl phosphate, pNPP. The substrate solution turns yellow when the pNPP is cleaved by the alkaline phosphatase.

The optical density (OD) is measured in a standard ELISA reader at a wavelength of 405 nm. The OD value corrected for background is proportional to the RT activity in the sample.

The detection step is performed as described below. A step-by-step procedure is provided in the written instructions or user's manual included with each kit. The compositions  
5 of the buffer solutions are given in table 4.

After the reverse transcriptase assay, the microtiter plate is washed either using one of the commercially available ELISA plate washers or by serially immersing the plate in buckets with the washing buffer. The conjugated antibody is optionally provided in the kit in lyophilized form. After reconstitution with 1% triton X-100 in double distilled water 100 µl of  
10 the antibody solution is added to each well and the microtiter plate is incubated at 33°C for 90 minutes. To remove excess antibody, the plate is subsequently washed in the same manner a second time. The substrate solution is prepared from buffer and pNPP tablets optionally provided with the kit. The OD values are then measured at suitable time intervals.

The linear relationship between amount of alkaline phosphatase enzyme bound  
15 and the concentration of the yellow product breaks down at high OD values. By measuring the OD at different times it is possible to get useful values, i.e. OD values within the linear reading range of the particular instrument, for samples with both high and low amounts of product formed during the reverse transcriptase assay step. The reference RT enzymes optionally included in some but not all of the kits are calibrated to give titration curves with  
20 useful OD values when the OD is measured after 30 min, 2 hours and 16-20 hours, i.e. overnight.

The improved performance obtained with the RT assay kits of the invention is demonstrated in Table 5. HIV-1 RT titration curves were obtained with the previously known Lenti RT kit from Cavid Tech AB and with an assay kit of the present invention. The OD  
25 values can be plotted against the RT enzyme concentration and fitted to a straight line using least squares fit. The k values in Table 6 are the slopes of the calculated straight lines and are a measure of the sensitivity of the assay. It can be seen that the assay kits of the invention have k-values that are an order of magnitude higher. In practical terms this translates to useful measurements from samples containing a much lower concentration of HIV-1 reverse  
30 transcriptase and/or to time-saving. Shorter reverse transcriptase assay times and/or a shorter alkaline phosphatase reading time means shorter turn-around time for users of the kits of the present invention.

## TYPICAL COMPONENTS OF THE KIT OF THE INVENTION

- A. Two 96-well microtitre plates with prA and/or pdA attached.
- B. A sample dilution and reaction buffer containing a RT type adapted mixture of components I-IX listed in Table 2.
- 5 C. Lyophilized reaction components X-XII mixed or provided in separate vials.
- D. Lyophilized reference enzyme either recombinant, purified natural or viral particles.
- E. Concentrated Washing Buffer
- F. Lyophilized alkaline phosphatase conjugated anti-BrdU monoclonal antibody, denoted "RT Product Tracer"
- 10 G. Alkaline phosphatase substrate buffer and pNPP tablets
- H. Written instructions or Manual

## EXAMPLES

Example 1

Improved detection of PERV (porcine endogenous retrovirus) RT in cell supernatants.

- 15 The porcine cell line PK-15 (porcine kidney) is known to continuously produce small amounts of PERV. Supernatants from a culture of PK15 cells were serially diluted. The capacity of the C- type RT assay of Cavid tech AB and the  $Mn^{2+}$  assay of the current invention to detect RT activity at each dilution were tested. The data shown in figure 1 originate from an over-night-RT assay.

- 20 The assay kit of the invention exhibits an approximately 25 times increased sensitivity compared to the one of previous art. It was not possible to use more sample to compensate for the difference in detection sensitivity, since the C-type assay suffered from increased background levels and deviations from linearity with time and/or sample amount at higher supernatant concentrations ( $>2 \mu l$  /well).

- 25 The assay kit of the invention can be used in studies regarding the possible transfer of exogenous retrovirus and/or activation of endogenous retrovirus in conjunction with xenotransplantation.

Example 2

Direct measurement of reverse transcriptase in synovial fluids.

- 30 Recent DNA hybridization experiments have suggested the association between certain rheumatic disorders and the presence of retrovirus associated sequences. Frozen samples of synovial fluids from patients with rheumatoid arthritis were obtained from the department of Rheumatology at Karolinska sjukhuset, Stockholm, Sweden. The samples had

been cleared from cells and debris by low speed centrifugation before freezing. The samples were thawed, serially diluted and investigated for RT activity.

The activities obtained were recalculated to OD<sub>405</sub>/h. Figure 2 presents the RT activities found using 1 µl sample and an over-night enzyme reaction in the synovial fluid RT assay of the invention. No RT activity was detected in any of the investigated samples by the Lenti or C-type RT assay of Cavid Tech AB.

### Example 3.

Detection of RT activity in extracts from human breast cancer.

An exogenous or endogenous human counterpart to the (mouse mammary tumor virus) MMTV has been implicated in the etiology of human breast cancer. Using recombinant MMTV RT to optimize the assay conditions, RT activity could be detected in extracts from breast cancers without prior concentration or purification. Frozen extracts from human breast cancers were obtained from the department of Oncology at Akademiska sjukhuset, Uppsala, Sweden. The tumor tissue had been homogenized and suspended in a standard buffer (pH 7.4). Supernatants were collected after clarification by low speed centrifugation. The samples were thawed, serially diluted and investigated for presence of RT activity in the Mg<sup>2+</sup> RT assay of the invention and the Lenti or C-type RT assay of Cavid Tech AB.

Figure 3 shows a representative example of the results obtained using an over-night RT reaction combined with 2 hours AP reaction. The difference in detection sensitivity between the Mg<sup>2+</sup> RT assay of the invention and the Lenti RT assay of Cavid Tech AB was approximately 400 times. No activity was detected in the C-type RT assay of Cavid Tech AB.

Figure 4 illustrates the variation of the RT activities detected by the Mg<sup>2+</sup> RT assay in tumor extracts from different patients.

The assay kit of the invention can be used in studies regarding the possible role of exogenous or endogenous retroviruses in the etiology of breast cancer as well as be used for diagnostic purposes.

### Example 4.

Detection of (human T-cells leukemia virus) HTLV like viruses in supernatants from cell cultures.

Some HTLV infected individuals go on to develop oncological or myelopathic disorders. In certain parts of Japan and South Asia the associated disease adult T-cell

leukemia was first described. A neurological disorder, tropical spastic paraparesis, was initially described in patients from the Caribbean. Methods capable of detecting exposure to the virus and/ or the continued presence of low levels viral activity is desirable.

A highly related bovine virus, bovine leukemia virus (BLV) is a pathogen in cows with great economic consequences for the dairy and cattle breeding industries. BLV was used to optimize an assay for BLV/HTLV RT activity.

Figure 5A illustrates the difference in detection sensitivity between the assay kit of the invention and the Lenti RT assay of Cavid Tech AB. Cell culture supernatants from the HTLV 1 transformed cell line MT-2 were serially diluted and the two RT assays were used to determine the amount of RT activity in each sample. The RT reaction time used was over-night (14 hours).

Figure 5B shows the corresponding data from a dilution set of supernatants from FLK-BLV cells. (This cell line is chronically infected by BLV).

The total gain in detection sensitivity was approximately 25 fold for the HTLV enzyme and 30-fold for the BLV enzyme, respectively. The increase in sensitivity was essential to obtain a significant signal from the supernatant of the MT-2 cells.

#### Example 5.

Direct determination of RT activity in crude sera from SIV infected macaques.

Quantification of RT activity in serum can be used for detection of virus replication during acute lenti virus infection. The serum RT activity is later, quenched by the production of RT inhibitory antibody.

A group of four cynomolgus macaques (*Macaca fascicularis*) engaged as untreated controls in a treatment study were infected with ten monkey infectious doses (MID50) of SIVsm. Serum sampled at indicated times after infection was serially diluted and assayed for RT activity utilizing the Lenti RT assay of the invention. Five µl serum samples were included in a four hours RT reaction and the absorbance values obtained were recalculated into OD<sub>405</sub>/h and plotted against days after infection, see Figure 6.

The Lenti RT assay of the invention is sensitive enough to detect virus replication by analysis of serum sampled during acute stage infection. The tests currently used for screening for HIV positivity among human blood donors is based on detection of antibodies towards HIV-1 proteins and fail to detect infected persons during the acute stage of the infection. These tests are in some countries supplemented by detection of viral antigen by ELISA or viral genome by PCR. Both types of tests may fail to detect deviant virus strains

due to the large genetic and immunological variation among HIV viruses. RT has an indispensable function for the replication of all retroviruses and the current assay offers an attractive alternative for detection of acute infections.

**Table 1**

Procedure for producing prA coated NucleoLink™ microtiter plates

Coupling solution	100 mM 1 mg/ml	1-methylimidazole pH 6.25 polyriboadenylic acid
Wash buffer	10 mM	Bis-Tris Propane pH 6.25

- 5 Add 100 µl coupling solution to each well.  
Incubate plates at room temperature for 2 h.  
Wash each well with 2x300 µl wash buffer.  
Dry the plates at 37 °C for 25 minutes.  
Put the plates in foil bags and vacuum seal them.
- 10 Store at -20 °C.

**Table 2**

Components used to compose RT type adapted reverse transcriptase assays

Component	Substance	Useful concentration range in final reaction mixture
I Buffer	Tris, Hepes	10-100 mM; pH 7.0-8.0
II Divalent metal ion	Mg <sup>2+</sup> , Mn <sup>2+</sup>	0-20 mM
III Chelator	EDTA, EGTA	0-0.5 mM
IV Polyamine	Spermine, Spermidine	0-20 mM
V RNase inhibitor	Heparin sulfate, Dextran sulfate	0-100 µg/ml
VI Reducing agent	DTT, DTE, Glutathione	0-5mM
VII Salt	NaCl, KCl	0-100mM
VIII Stabilising agent	NCS, BSA	0-1 mg/ml
IX Detergent	Tween 20, Triton X-100	0-1.0%
X Deoxynucleotide triphosphate	BrdUTP	1-50 µM
XI Primer	oligo dT	5-100 ng/ml
XII Protective agent	ATP, GTP, CTP	0-5mM



## Abbreviations:

EDTA	Ethylenediaminetetraacetic Acid
EGTA	ethylene glycol-bis( $\beta$ -aminoethyl ether) N,N,N',N'-tetraacetic acid
DTT	Dithiothreitol
DTE	Dithioerythritol
NCS	Newborn Calf serum
BSA	Bovine serum albumin

**Table 3**

Components in optimized Lenti reverse transcriptase assay of the invention

	Component	Substance	Concentration in final reaction mixture
I	Buffer	Hepes-HCl	10 mM; pH 7.6
II	Divalent metal ion	MgCl <sub>2</sub>	4 mM
III	Chelator	EGTA	0.2 mM
IV	Polyamine	Spermine	2 mM
V	RNase inhibitor	Dextran sulfate	50 $\mu$ g/ml
VI	Reducing agent		
VII	Salt		
VIII	Stabilising agent	BSA	0.5 mg/ml
IX	Detergent	Triton X-100	0.5%
X	Deoxynucleotide triphosphate	BrdUTP	16 $\mu$ M
XI	Primer	oligo dT	80 ng/ml
XII	Protective agent	GTP	0.5 mM
	Preservative	NaN <sub>3</sub>	1.92 mM

**Table 3 (cont.)**

Components in optimized BLV/HTLV reverse transcriptase assay of the invention

	Component	Substance	Concentration in final reaction mixture
I	Buffer	Hepes-HCl	10 mM; pH 7.8
II	Divalent metal ion	MgCl <sub>2</sub>	8 mM
III	Chelator	EGTA	0.2 mM
IV	Polyamine	Spermidine	1 mM
V	RNase inhibitor	Dextran sulfate	2 µg/ml
VI	Reducing agent	Glutathione	0.6 mM
VII	Salt		
VIII	Stabilising agent	BSA	0.5 mg/ml
		NCS	0.5%
IX	Detergent	Triton X-100	0.5%
X	Deoxynucleotide triphosphate	BrdUTP	16 µM
XI	Primer	oligo dT	80 ng/ml
XII	Protective agent	GTP	0.5mM
	Preservative	NaN <sub>3</sub>	1.92 mM

5

Components in optimized Mg<sup>2+</sup> reverse transcriptase assay of the invention

	Component	Substance	Concentration in final reaction mixture
I	Buffer	Hepes-HCl	10 mM; pH 7.6
II	Divalent metal ion	MgCl <sub>2</sub>	25 mM
III	Chelator	EGTA	2.5 mM
IV	Polyamine	Spermine	0.15 mM
		Spermidine	3 mM
V	RNase inhibitor		
VI	Reducing agent	Glutathione	1 mM
VII	Salt		
VIII	Stabilising agent	BSA	0.5 mg/ml
		NCS	0.25%
IX	Detergent	Triton X-100	0.5%
X	Deoxynucleotide triphosphate	BrdUTP	16 µM
XI	Primer	oligo dT	80 ng/ml
XII	Protective agent	ATP, GTP	0.5mM
	Preservative	NaN <sub>3</sub>	1.92 mM

Table 3 (cont.)

Components in optimized Mn <sup>2+</sup> reverse transcriptase assay of the invention			
	Component	Substance	Concentration in final reaction mixture
I	Buffer	Hepes-HCl	10 mM; pH 7.5
II	Divalent metal ion	MnCl <sub>2</sub>	6 mM
III	Chelator	EDTA	0.3 mM
IV	Polyamine	Spermidine	12 mM
V	RNase inhibitor		
VI	Reducing agent	Glutathione	4 mM
VII	Salt		
VIII	Stabilising agent	BSA	0.2 mg/ml
IX	Detergent	Triton X-100	0.5%
X	Deoxynucleotide triphosphate	BrdUTP	16 µM
XI	Primer	oligo dT	80 ng/ml
XII	Protective agent	GTP	0.5mM
	Preservative	NaN <sub>3</sub>	1.92 mM

5

Components in synovial fluid reverse transcriptase assay of the invention			
	Component	Substance	Concentration in final reaction mixture
I	Buffer	Hepes-HCl	10 mM; pH 7.6
II	Divalent metal ion	MnCl <sub>2</sub>	1.2 mM
III	Chelator	EDTA	0.13 mM
IV	Polyamine	Spermidine	8 mM
V	RNase inhibitor	Dextran sulfate	17 µg/ml
VI	Reducing agent	Glutathione	0.3 mM
VII	Salt	KCl	20 mM
VIII	Stabilising agent	BSA	0.3 mg/ml
IX	Detergent	Triton X-100	0.5%
X	Deoxynucleotide triphosphate	BrdUTP	16 µM
XI	Primer	oligo dT	80 ng/ml
XII	Protective agent	GTP	0.5mM
	Preservative	NaN <sub>3</sub>	1.92 mM

**Table 4**

## Components in the detection system

## Washing buffer

3 mM	Tris-HCl , pH 8.6
0.01%	Tween-20
0.75 %	Triton X-100

## Buffer for anti-BrdUTP monoclonal antibody

25mM	Bis-Tris propane pH 8.9
250mg/ml	Non-fat dried milk
0.01%	Tween-20
1%	Triton X-100
1.92 mM	NaN <sub>3</sub>

## Alkaline phosphatase substrate solution

200 mM	Tris-HCl , pH 9.8
1 mM	MgCl <sub>2</sub>
0.5mg/ml	pNPP
3.9 mM	NaN <sub>3</sub>

**Table 5**

- 5 Correlation between RT enzyme concentration and OD values obtained with the Lenti RT assay from CaviDi Tech and the improved assay of the invention.

10	Lenti RT assay from CaviDi Tech		Improved assay
	pg/ml	3hr RT/30 min AP	3 hr RT/30 min AP
	1240	1.274	nd
	551	0.594	nd
	245	0.332	9.999
	109	0.175	1.837
	48.4	0.108	0.989
	21.5	0.070	0.525
	9.6	0.052	0.264
	4.25	0.046	0.174
	1.89	0.054	0.121
	0.839	0.041	0.101
	0.373	0.042	0.091
	0.166	0.040	0.081
	0.074	nd	0.075
	0.033	nd	0.075
	0	0.042	0.078

pg/ml	over night RT/2hr AP	over night RT/2hr AP
1240	9.999	nd
551	9.999	nd
245	9.999	9.999
109	9.999	9.999
48.4	1.91	9.999
21.5	0.961	9.999
9.6	0.55	9.999
4.25	0.267	2.283
1.89	0.148	1.134
0.839	0.094	0.6
0.373	0.075	0.334
0.166	0.056	0.198
0.074	nd	0.144
0.033	nd	0.124
0	0.048	0.094

pg/ml	over night RT/- over night AP	over night RT/- over night AP
1240	9.999	nd
551	9.999	nd
245	9.999	9.999
109	9.999	9.999
48.4	9.999	9.999
21.5	9.999	9.999
9.6	9.999	9.999
4.25	2.217	9.999
1.89	1.155	9.999
0.839	0.595	9.999
0.373	0.403	2.289
0.166	0.191	1.171
0.074	nd	0.701
0.033	nd	0.577
0	0.115	0.251

nd=not done

**Table 6**

k values obtained with the Lenti RT assay from Cavid Tech  
and the improved Lenti RT assay of the invention

Lenti RT assay from Cavid Tech		Improved assay	
	k value		k value
3hr RT/30 min AP	0.0012	3 hr RT/30 min AP	0.0165
over night RT/2hr AP	0.0432	over night RT/2hr AP	0.5145
over night RT/- over night AP	0.5453	over night RT/- over night AP	5.2827

**References**

- Baltimore D. (1970) RNA-dependent DNA polymerase in virions of RNA tumour viruses. *Nature* 226:1209-1211.
- Baltimore D, Smoler D (1971) Primer requirement and template specificity of the DNA  
5 polymerase of RNA tumor viruses. *PNAS* 68, 1507-11.
- Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 220(4599):868-71.
- 10 Bird RE, Chang-Yeh A. (1996) Methods and kits for detecting viral transcriptase activity in a sample using an acidic pH or an elevated temperature. *US5817457*.
- Di Cristofano A, Strazullo M, Longo L, La Mantia G (1995) Characterization and genomic mapping of the ZNF80 locus: expression of this zinc-finger gene is driven by a solitary LTR of ERV9 endogenous retroviral family. *Nucleic Acids Res* 23(15):2823-30.
- 15 Duvic M (1995) Human immunodeficiency virus and the skin: selected controversies. *J Invest Dermatol* 105(1 Suppl):117S-121S.
- Eberle J, and R. Seibl. (1992) A new method for measuring reverse transcriptase activity by ELISA. *J.Virol.Methods* 40:347-356.
- Ekstrand D.H.L., Awad R.J-K., Källander C.F.R. and Gronowitz J.S. (1996) A sensitive assay  
20 for the detection and quantification of RT activity, based on the use of carrier bound template and non-radioactive product detection, with special reference to HIV isolation. *Biotechnology and Applied Biochemistry*. 23, 95-105.
- Faff O, Murray AB, Schmidt J, Leib-Mösch C, Erfle V, Hehlmann R, Thelen K, Löwer J, Kurth R (1992). Retrovirus-like particles from the human T47D cell line are related to  
25 mouse mammary tumour virus and are of human endogenous origin. *J Gen Virol* 73: 1087-97.
- Ghosh SS, Musso GF (1987) Covalent attachment of oligonucleotides to solid supports. *Nucleic Acids Res* 15(13):5353-72.
- Goff S.P. (1990) Retrovirus reverse transcriptase: Synthesis, Structure and Function. Review.  
30 *J.Acquir.Imm.Defic.Syindr.* 3:817-31.

- Gregorius K, Mouritsen S, Elsner HI (1995) Hydrocoating: a new method for coupling biomolecules to solid phases. *J Immunol Methods* 181(1):65-73.
- Gronowitz JS., Neumüller M., Lennerstrand J., Bhikabhai R., Unge T., Weltman H & Källander CFR. (1991) Carrier bound templates for single tube reverse transcriptase assays and for combined purification and activity analyses, with special reference to HIV.  
5 *Biotech.Appl.Biochem* 13:127-142.
- Gupta, P., Balachandran, Grovit, K., Webster, D., and Rinaldo. C. (1987) *J.Clin.Microbiol.* 25, 1122-1125.
- Heneine W, Yamamoto S, Switzer WM, Spira TJ, Folks TM. (1995) Detection of reverse  
10 transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. *J Infect Dis* 171:1210-1216
- Heneine W, Folks; Thomas M, Switzer W M, Yamamoto S. (1995) Methods for sensitive detection of reverse transcriptase. *US5849494*:
- Jackson, B., Sannerud, K., Rhame, F., Tsang, R., and Balfour, H.H. (1987) *Diagn. Microbiol.*  
15 *Infect. Dis.* 7, 185-192.
- Krieg AM, Steinberg AD (1990) Retroviruses and autoimmunity. *J Autoimmun.* 3(2):137-66
- Krieg AM, Gourley MF, Perl A (1992) Endogenous retroviruses: potential etiologic agents in autoimmunity. *FASEB J* 6(8):2537-44.
- Källander CFR, Gronowitz JS, Neumüller TM, Karlström RA, Långström-Persson UM.  
20 (1988). Method for polymerase activity determination. Svensk patent no 8804344-3, *EP 0 447 442 B1*.
- Lee M., Sano K., Morales F.E., and D.T. Imagawa. (1987) Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. *J.Clin.Microbiol.* 25:1717-21.
- 25 Leib-Mösch C and Seifarth W (1996) Evolution and biological significance of human retroelements. *Virus genes* 11: 133-145.
- Löwer R, Löwer J, Kurth R (1996) The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. *Proc Natl Acad Sci U S A* 93(11):5177-84.



- Martinelli SC, Goff SP (1990) Rapid reversion of a deletion mutation in Moloney murine leukemia virus by recombination with a closely related endogenous provirus. *Virology* 174(1):135-44.
- 5 Meese E, Gottert E, Zang KD, Sauter M, Schommer S, Mueller-Lantzsch N (1996) Human endogenous retroviral element k10 (HERV-K10): chromosomal localization by somatic hybrid mapping and fluorescence in situ hybridization. *Cytogenet Cell Genet* 72(1):40-2.
- 10 Neumüller M., Karlström A.R., Källander C.F.R., and J.S. Gronowitz. (1990) Improved assays for DNA-polymerizing enzymes by the use of enzymatically synthesized 5-(<sup>125</sup>I)iodo-2'-deoxyuridine triphosphate, illustrated by direct quantitation of anti-HIV reverse transcriptase antibody and by serum DNA polymerase analyses. *Biotech.Appl.Biochem.* 12:34-56.
- Niveleau A, Sage D, Reynaud C, Bruno C, Legastelois S, Thomas V, Dante R (1993) Covalent linking of haptens, proteins and nucleic acids to a modified polystyrene support. *Immunol Methods* 159(1-2):177-87.
- 15 Porstmann T., Meissner K., Glaser R., Döpel S-H., and G. Sydow. (1991) A sensitive non radioactive assay specific for HIV associated reverse transcriptase. *J. Virol.Meth.* 31:181-188.
- Rasmussen SR, Larsen MR, Rasmussen SE (1991) Covalent immobilization of DNA onto polystyrene microwells: the molecules are only bound at the 5' end. *Anal Biochem* 20 198(1):138-42.
- Silver J, Maudru T, Fujita K and Repaske R. (1993) An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. *Nucleic Acids Res* 21:3593-3594.
- 25 Temin HM, Mizutani S. (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. *Nature* 226:1211-1213.
- Tönjes RR, Boller K, Limbach C, Lugert R, Kurth R. Characterization of human endogenous retrovirus type K virus-like particles generated from recombinant baculoviruses.( 1997) *Virology* 233(2):280-91.
- 30 Urabe T, Sano K, Nakano T, Odawara F, Lee MH, Otake T, *et al.* (1994) Differentiation between human immunodeficiency virus type 1 (HIV-1) and HIV-2 isolates by nonradioisotopic reverse transcriptase-typing assay. *J Clin Microbiol*; 32:1870-75.

Urnovitz HB, and Murphy WH (1996) Human endogenous retroviruses: Nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev 9: 72-99.

Weiss R: The search for human RNA tumor viruses. In R Weiss, N Teich, H Varmus, and J Coffin (eds) RNA Tumor viruses (2<sup>nd</sup> ed vol 1) 1205 1281. Cold Spring Harbor Laboratory Press, . Cold Spring Harbor, New York, 1984.

Wilkinson DA Mager DL and Leong J-A (1994). Endogenous human retroviruses. In "The Retroviridae"(JA Levy, Ed), vol 3,pp 465-535. 3 vols Plenum Press, New York.

Zammatteo N, Girardeaux C, Delforge D, Pireaux JJ, Remacle J (1996) Amination of polystyrene microwells: application to the covalent grafting of DNA probes for hybridization assays. Anal Biochem 236(1):85-94.

Zinkernagel RM, Cooper S, Chambers J, Lazzarini RA, Hengartner H, Arnheiter H (1990) Virus-induced autoantibody response to a transgenic viral antigen. Nature 345: 68-71.

## Claims

1. Reverse transcriptase (RT) assay kit comprising one or several package(s) containing solid phase bound polyriboadenylic acid (prA) and/or polydeoxyadenylic acid (pdA) template(s) obtainable by contacting a polystyrene-based solid phase with a coupling solution comprising 1-methylimidazole, and prA and/or pdA, followed by incubation, washing with a wash buffer, drying and packaging, RT-type adapted separately packaged assay components selected from the group consisting of a mixture of or separately a buffer,  $\text{pH} \cong 7-8$ , divalent metal ion, chelator, polyamine, RNase inhibitor, reducing agent, salt, stabilizing agent, and detergent, and a mixture of or separately lyophilized deoxynucleotide triphosphate, primer, protective agent and a concentrated washing buffer, and optionally lyophilized reference enzyme(s), and optionally components of a detection system comprising lyophilized alkaline phosphatase conjugated anti-BrdU monoclonal antibody, alkaline phosphatase substrate buffer and alkaline phosphatase substrate, and written instructions for use of the assay kit.

2. RT assay kit according to claim 1, wherein the solid phase is a microtiter plate and an aliquot of the coupling solution, which comprises 100 mM 1-methylimidazole,  $\text{pH} \cong 5-7$ , and 0.5 - 2 mg/ml prA and/or pdA, is added to each well, followed by the incubation at a temperature of 10 - 60 °C for 0.5 - 10 h, and washing each well for the removal of the 1-methylimidazole with the wash buffer, which comprises Bis-Tris propane,  $\text{pH} \cong 5-7$ , and drying and packaging the plates.

3. RT assay kit according to claim 2, wherein 100  $\mu\text{l}$  of the coupling solution, which comprises 100 mM 1-methylimidazole,  $\text{pH} \cong 6.25$ , and 1mg/ml prA and/or pdA, is added to each well, followed by the incubation at room temperature for  $\cong 2$  h, washing of each well with 2x300  $\mu\text{l}$  of the wash buffer, which comprises 10mM Bis-Tris propane,  $\text{pH} \cong 6.25$ , drying the plates at 37 °C for  $\cong 25$  minutes and putting the plates in foil bags and vacuum sealing the bags.

4. RT assay kit according to any one of claims 1 - 3, wherein the assay components are selected from the group consisting of the buffers Tris and Hepes,  $\text{pH} \cong 7-8$ , the divalent metal ions  $\text{Mg}^{2+}$  and  $\text{Mn}^{2+}$ , the chelators ethylenediaminetetraacetic acid (EDTA) and ethylene glycol-bis( $\beta$ -aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) and, the

polyamines spermine and spermidine, the RNase inhibitors heparin sulfate and dextran sulfate, the reducing agents dithiothreitol (DTT), dithioerythritol (DTE), and glutathione, the salts NaCl and KCl, the stabilizing agents newborn calf serum (NCS) and bovine serum albumin (BSA), the detergents Tween 20 and Triton X-100, the deoxynucleotide triphosphate  
5 BrdUTP, the primer oligo dT, and the protective agent agents ATP, GTP and CTP.

5. Use of an assay kit according to any one of claims 1 - 4 for the qualitative and quantitative analysis of RT activity in a biological sample.

6. Use according to claim 5, wherein the biological sample is selected from biological fluids and cell extracts.

10 7. Use according to claim 6, wherein the biological fluid is selected from plasma, serum, spinal fluid, synovial fluid and pleural fluid.

8. Use according to any one of claims 5 - 7 followed by evaluation of the status of a RT activity related disorder or disease based on the result of the analysis of the RT activity.

15 9. Method of qualitative and quantitative analysis of RT activity in a biological sample comprising the steps of using and following the written instructions for the RT assay kit according to any one of claims 1 - 4 for the determination of the RT activity in the biological sample.

20 10. Method according to claim 9, wherein the biological sample is selected from biological fluids and cell extracts.

11. Method according to claim 10, wherein the biological fluid is selected from plasma, serum, spinal fluid, synovial fluid and pleural fluid.

25 12. Method according to any one of claims 9 - 11 followed by evaluation of the status of a RT activity related disorder or disease based on the result of the analysis of the RT activity.

Figure 1




Figure 2




Figure 3







Figure 4



Figur 5



**Figure 6**



RECD 23 AUG 2001

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 192977501/BN	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/05563	International filing date (day/month/year) 16/06/2000	Priority date (day/month/year) 24/06/1999
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant CAVIDI TECH AB et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  22/01/2001	Date of completion of this report  20.08.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Wieser, M  Telephone No. +49 89 2399 8434  

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/05563

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-25 as originally filed

**Claims, No.:**

1-12 as originally filed

**Drawings, sheets:**

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/05563

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims 1-12
	No: Claims
Inventive step (IS)	Yes: Claims 1-12
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-12
	No: Claims

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

## **Section V**

The following documents mentioned in the International Search Report are considered as being the most relevant prior art:

D1: EKSTRAND D HENRIC L ET AL: 'A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation.' BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 23, no. 2, 1996, pages 95-105, XP000979588 ISSN: 0885-4513 cited in the application

1. The RT-assay kit according to claim 1, containing prA and /or pdA templates bound to a polystyrene based solid phase via a coupling solution comprising 1-methylimidazole, is not disclosed in the known prior art, and is considered to be novel (Article 33(3) PCT).

The same applies to dependent claims 2-4, to claims 5-12, referring to the use of said kit and to a method using it.

2. The closest prior art results from D1. The subject-matter of claim 1 is distinguished from the disclosure in D1 by the method to prepare the prA/pdA coated solid phase. D1 reads on page 97, left paragraph: "*Various amounts of prA were evaluated and linkage was performed by a standard procedure [16].*" Reference [16] refers to Journal of Virological Methods, vol.44, pages 189-198, which on page 191, second full paragraph, discloses a method for coating a microtiterplate with poly A, wherein a mixture of hydroxysulfosuccinimide and carbodiimide is used as coupling agent.

Neither D1, nor reference [16] cited therein, mentions the coupling agent used for producing the solid phase of claim 1. Moreover, the Applicant has convincingly proved in examples 1-4 (see table 5) that the claimed assay kit has a major benefit over the prior art by showing drastically increased assay sensitivity.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/05563

Accordingly, claim 1, as well as claims 2-12, are based on an inventive concept (Article 33(3) PCT).

**Section VIII**

Claim 1 refers to a kit, which is considered as being a composition of substances and/or entities. The claim comprises as an additional feature instructions for the use of the kit components. Such instructions are considered as characterizing a method using the kit, rather than the kit per se, and as such obscure the scope of the claim since its category is no longer clear (Article 6 PCT).

**P NT COOPERATION TREATY**

**PCT**

**INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>192977501/BN</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/EP 00/ 05563</b>	International filing date (day/month/year) <b>16/06/2000</b>	(Earliest) Priority Date (day/month/year) <b>24/06/1999</b>
Applicant  <b>CAVIDI TECH AB</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International Application No

PC 00/05563

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EKSTRAND D HENRIC L ET AL: "A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation." BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 23, no. 2, 1996, pages 95-105, XP000979588 ISSN: 0885-4513 cited in the application the whole document</p> <p style="text-align: center;">--- -/--</p>	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

7 February 2001

Date of mailing of the international search report

20/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gabriels, J

## INTERNATIONAL SEARCH REPORT

International Application No

PC 00/05563

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHAO X ET AL: "A non-radioactive microtitre plate reverse transcriptase (RT) assay, based on immobilized template, for screening of RT activity inhibitors and evaluation of the mode of action." ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 8, no. 2, 1997, pages 149-159, XP000981902 ISSN: 0956-3202 page 150, column 2 -page 152, column 1; figure 1A ---	1-12
X	AWAD RAYMOND J -K ET AL: "Measurement of levels of human immunodeficiency virus type 1 reverse transcriptase (RT) and RT activity-blocking antibody in human serum by a new standardized colorimetric assay." JOURNAL OF CLINICAL MICROBIOLOGY, vol. 35, no. 5, 1997, pages 1080-1089, XP002159505 ISSN: 0095-1137 page 1080 -page 1082, column 1 ---	1-12
A	DATABASE WPI Week 0014 Derwent Publications Ltd., London, GB; AN 1992-223246 XP002159753 "Reverse transcriptase determ.-by using hybridized substance of solidified primer and template RNA" & JP 04 148698 A (TOYO JOZO KK), 21 May 1992 (1992-05-21) abstract -----	1-12



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC/JP 00/05563

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 04148698 A	21-05-1992	JP 3011988 B	21-02-2000

VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT  
AUF DEM GEBIET DES PATENTWESENS

# PCT

## INTERNATIONALER RECHERCHENBERICHT

(Artikel 18 sowie Regeln 43 und 44 PCT)

Aktenzeichen des Anmelders oder Anwalts <b>P20013W0</b>	<b>WEITERES VORGEHEN</b> siehe Mitteilung über die Übermittlung des internationalen Recherchenberichts (Formblatt PCT/ISA/220) sowie, soweit zutreffend, nachstehender Punkt 5	
Internationales Aktenzeichen <b>PCT/EP 00/ 05560</b>	Internationales Anmeldedatum (Tag/Monat/Jahr) <b>16/06/2000</b>	(Frühestes) Prioritätsdatum (Tag/Monat/Jahr)

Anmelder

**ZSCHIMMER & SCHWARZ GMBH & CO. CHEMISCHE FABRIKEN**

Dieser internationale Recherchenbericht wurde von der Internationalen Recherchenbehörde erstellt und wird dem Anmelder gemäß Artikel 18 übermittelt. Eine Kopie wird dem Internationalen Büro übermittelt.

Dieser internationale Recherchenbericht umfaßt insgesamt 2 Blätter.



Darüber hinaus liegt ihm jeweils eine Kopie der in diesem Bericht genannten Unterlagen zum Stand der Technik bei.

### 1. Grundlage des Berichts

- a. Hinsichtlich der **Sprache** ist die internationale Recherche auf der Grundlage der internationalen Anmeldung in der Sprache durchgeführt worden, in der sie eingereicht wurde, sofern unter diesem Punkt nichts anderes angegeben ist.



Die internationale Recherche ist auf der Grundlage einer bei der Behörde eingereichten Übersetzung der internationalen Anmeldung (Regel 23.1 b)) durchgeführt worden.

- b. Hinsichtlich der in der internationalen Anmeldung offenbarten **Nucleotid- und/oder Aminosäuresequenz** ist die internationale Recherche auf der Grundlage des Sequenzprotokolls durchgeführt worden, das



in der internationalen Anmeldung in Schriftlicher Form enthalten ist.



zusammen mit der internationalen Anmeldung in computerlesbarer Form eingereicht worden ist.



bei der Behörde nachträglich in schriftlicher Form eingereicht worden ist.



bei der Behörde nachträglich in computerlesbarer Form eingereicht worden ist.



Die Erklärung, daß das nachträglich eingereichte schriftliche Sequenzprotokoll nicht über den Offenbarungsgehalt der internationalen Anmeldung im Anmeldezeitpunkt hinausgeht, wurde vorgelegt.



Die Erklärung, daß die in computerlesbarer Form erfaßten Informationen dem schriftlichen Sequenzprotokoll entsprechen, wurde vorgelegt.

2. ☐ Bestimmte Ansprüche haben sich als nicht recherchierbar erwiesen (siehe Feld I).

3. ☐ Mangelnde Einheitlichkeit der Erfindung (siehe Feld II).

### 4. Hinsichtlich der Bezeichnung der Erfindung



wird der vom Anmelder eingereichte Wortlaut genehmigt.



wurde der Wortlaut von der Behörde wie folgt festgesetzt:

### 5. Hinsichtlich der Zusammenfassung



wird der vom Anmelder eingereichte Wortlaut genehmigt.



wurde der Wortlaut nach Regel 38.2b) in der in Feld III angegebenen Fassung von der Behörde festgesetzt. Der Anmelder kann der Behörde innerhalb eines Monats nach dem Datum der Absendung dieses internationalen Recherchenberichts eine Stellungnahme vorlegen.

6. Folgende Abbildung der **Zeichnungen** ist mit der Zusammenfassung zu veröffentlichen: Abb. Nr. \_\_\_\_\_



wie vom Anmelder vorgeschlagen



weil der Anmelder selbst keine Abbildung vorgeschlagen hat.



weil diese Abbildung die Erfindung besser kennzeichnet.



keine der Abb.

**A. KLASSIFIZIERUNG DES ANMELDUNGSGEGENSTANDES**

IPK 7 C14C9/02 C14C3/00

Nach der Internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK

**B. RECHERCHIERTE GEBIETE**

Recherchierter Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole)

IPK 7 C14C

Recherchierte aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen

Während der internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)

EPO-Internal, WPI Data, PAJ

**C. ALS WESENTLICH ANGESEHENE UNTERLAGEN**

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
Y	DE 197 46 445 A (TFL LEDERTECHNIK GMBH & CO KG) 22. April 1999 (1999-04-22) Seite 1, Zeile 8 - Seite 2, Zeile 40 Spalte 3, Zeile 55 - Spalte 4, Zeile 38 Ansprüche 1,6,7,13,20; Beispiele 6,7	1
Y	US 4 800 045 A (FRIESE HANS-HERBERT ET AL) 24. Januar 1989 (1989-01-24) Seite 1, Zeile 6 - Seite 4, Zeile 40 Beispiele 3,,A	1
A	GB 1 343 918 A (BASF AG) 16. Januar 1974 (1974-01-16) Seite 1, Zeile 66 - Zeile 98 Seite 2, Zeile 71 - Zeile 83	1,5

☐ Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen

☒ Siehe Anhang Patentfamilie

\* Besondere Kategorien von angegebenen Veröffentlichungen :

\*A\* Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist

\*E\* älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist

\*L\* Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt)

\*O\* Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht

\*P\* Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist

\*T\* Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist

\*X\* Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfinderischer Tätigkeit beruhend betrachtet werden

\*Y\* Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfinderischer Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist

\*Z\* Veröffentlichung, die Mitglied derselben Patentfamilie ist

Datum des Abschlusses der internationalen Recherche

6. Februar 2001

Absenddatum des internationalen Recherchenberichts

20/02/2001

Name und Postanschrift der Internationalen Recherchenbehörde  
Europäisches Patentamt, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Bevollmächtigter Bediensteter

Neugebauer, U

INTERNATIONAL-~~TYPE~~ SEARCH REPORT

Search request No.

SE 95/00892

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Biotechnol. Appl. Biochem. vol. 23, 1996, D. Henric L. Ekstrand et al: "A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation, page 95 - page 105  --	1-12
A	Journal of Virological Methods, Volume 44, 1993, Kazuo Suzuki et al, "Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase", page 189 - page 198, see especially page 191, lines 21-28  --	1-12

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international-type search

21 January 2000

Date of mailing of the international-type search report

2000 -01- 26

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson/EÖ  
Telephone No. +46 8 782 25 00

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9304199 A2 (SCIENTIFIC GENERICS LIMITED), 4 March 1993 (04.03.93), see especially page 32, lines 4-9  --	
A	US 5683875 A (KAY LICHTENWALTER), 4 November 1997 (04.11.97), see especially column 14, lines 24-30  --	1-12
A	Journal of Virological Methods, Volume 31, 1991, Tomas Porstmann et al, "A sensitive non-isotopic assay specific for HIV-1 associated reverse transcriptase" page 181 - page 188  --  -----	1-12

**INTERNATIONAL TYPE SEARCH REPORT**  
Information on patent family members

02/12/99

Search request No.  
SE 99/00892

WO	9304199	A2	04/03/93	NONE
US	5683875	A	04/11/97	NONE

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/00/05560

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19746445 A	22-04-1999	AU 4851397 A BR 9705614 A EP 0849365 A JP 10195500 A PL 323618 A US 6033590 A	25-06-1998 09-03-1999 24-06-1998 28-07-1998 22-06-1998 07-03-2000
US 4800045 A	24-01-1989	DE 3617691 A BR 8702670 A CA 1297887 A DE 3766005 D EP 0247490 A IN 168745 A JP 62285995 A MX 168644 B TR 22873 A US 4903362 A ZA 8703744 A	03-12-1987 23-02-1988 24-03-1992 13-12-1990 02-12-1987 01-06-1991 11-12-1987 02-06-1993 23-09-1988 27-02-1990 27-01-1988
GB 1343918 A	16-01-1974	DE 2056345 A ES 397095 A FR 2114800 A IT 944956 B	18-05-1972 01-03-1975 30-06-1972 20-04-1973

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 13 March 2001 (13.03.01)	
<b>International application No.</b> PCT/EP00/05563	<b>Applicant's or agent's file reference</b> 192977501/BN
<b>International filing date</b> (day/month/year) 16 June 2000 (16.06.00)	<b>Priority date</b> (day/month/year) 24 June 1999 (24.06.99)
<b>Applicant</b> KÄLLANDER, Clas et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 22 January 2001 (22.01.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Juan Cruz Telephone No.: (41-22) 338.83.38
---	---